PATENT CLAIM ANALYSIS

Application Number: 16032715
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "212060"]

Abstract:
Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

Claim (Index 24):
The compound of claim  1  wherein Q is \u2014(CR 3 )\u2014.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 95.0
- Lexical Diversity: 1.36
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15656176', '14787280', '14353381', '14431485', '15103893']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8376810044137025
- 35 USC 102 Novelty (BERT): 0.5839107459218221
- Combined Prediction Score: 0.8123039785645144
- Mean Citation Score: 463.273524
- Max Citation Score: 537.2629
- Similarity Product: 398.8793110790014

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test